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Abstract
Up to 20% of acute myeloid leukemia (AML) patients present initially with hyperleukocytosis, plac-
ing them at increased risk for early mortality during induction. Yet, it is unknown whether
hyperleukocytosis still retains prognostic value for AML patients undergoing hematopoietic stem
cell transplantation (HSCT). Furthermore, it is unknown whether hyperleukocytosis holds prognos-
tic significance when modern molecular markers such as FLT3-ITD and NPM1 are accounted for.
To determine whether hyperleukocytosis is an independent prognostic factor influencing outcome
in transplanted AML patients we performed a retrospective analysis using the registry of the acute
leukemia working party of the European Society of Blood and Marrow Transplantation. A cohort
of 357 patients with hyperleukocytosis (159 patients with white blood count [WBC] 50 K-100 K,
198 patients with WBC100 K) was compared to 918 patients without hyperleukocytosis.
Patients with hyperleukocytosis were younger, had an increased rate of favorable risk cytogenet-
ics, and more likely to be FLT3 and NPM1 mutated. In multivariate analysis, hyperleukocytosis was
independently associated with increased relapse incidence (hazard ratio [HR] of 1.55, 95% confi-
dence interval [CI], 1.14-2.12; P5 .004), decreased leukemia-free survival (HR of 1.38, 95% CI,
1.07-1.78; P5 .013), and inferior overall survival (HR of 1.4, 95% CI, 1.07-1.84; P5 .013). Hyper-
leukocytosis retains a significant prognostic role for AML patients undergoing HSCT.
1 | INTRODUCTION
A significant subset of newly diagnosed acute myeloid leukemia (AML)
patients, estimated at 5%-20%, present initially with an elevated white
blood count (WBC) exceeding 100,000/mL.1–5 Patients presenting in
like fashion are treated emergently as a substantial body of evidence
published over the past three decades conclusively shows that these
patients are at a significant risk for early death during initial induction
therapy.5–9 Risk factors for hyperleukocytosis (HL) include younger age
and leukemias skewed toward monocytic differentiation.10–12 Central
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to the pathogenesis of the increased mortality seen in hyperleukocytosis
patients are the aggregate detrimental effects of leukostasis, tumor lysis
syndrome, and disseminated intravascular coagulation. While hyperleu-
kocytosis is frequently defined at the 100 000 WBC threshold, adverse
hyperleukocytosis associated phenomenon are also seen at lower WBC
counts.13 However, it remains unclear whether the inferior prognosis
associated with hyperleukocytosis results from the high tumor burden
or rather is an inherent feature of a unique subtype of AML. To date, no
studies have examined the long term outcome of AML patients with
hyperleukocytosis who underwent hematopoietic stem cell transplanta-
tion (HSCT). In this analysis we address this question and analyze a large
cohort of patients with HL who underwent HSCT in first remission and
compare their clinical outcome with non-HL patients.
2 | METHODS
2.1 | Study design and data collection
This is a retrospective analysis based on the registry data of the acute
leukemia working party (ALWP) of the European Society of Blood and
Marrow Transplantation (EBMT). The EBMT is a voluntary working
group comprising more than 500 transplant centers that are required
to report all consecutive stem cell transplantations and follow-ups once
a year. Audits are routinely performed to determine the accuracy of
the data. This study was approved by the ALWP institutional review
board. The study was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines. All patients provided
written informed consent authorizing the use of their personal informa-
tion for research purposes. Eligibility criteria for this analysis included
adult non-M3 AML patients over 18 years of age who underwent a
first allogeneic stem cell transplantation at first complete remission
between 2005 and 2015. Hyperleukocytosis was defined as a WBC
count of over 50 000 WBC/mL. Cytogenetic risk was assessed accord-
ing to the European LeukemiaNet criteria.14 Intensity of conditioning
was determined according to EBMT published criteria.15 Stem cell
grafts consisted of either bone marrow (BM) or G-CSF mobilized
peripheral blood (PB). All donors were HLA-matched according to
standard criteria (locus-A, -B, -C, DRB1, -DQB1). Patients who had
undergone a previous stem cell transplantation were excluded from
the analysis. Grading of acute and chronic graft-versus-host disease
(GVHD) was performed using established criteria.16,17
2.2 | Statistical analysis
The clinical end points evaluated were leukemia-free survival (LFS),
relapse incidence (RI), nonrelapse mortality (NRM), acute and chronic
GVHD, GVHD-free/relapse-free survival, defined as events including
grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD,
relapse, or death in the first post-HCT year (GRFS), and overall survival
(OS). LFS was defined as survival with no evidence of relapse or pro-
gression. Relapse was defined as the reappearance of 5% BM blasts
and/or extramedullary lesion due to specific blast cell infiltration. NRM
was defined as death without evidence of relapse or progression. OS was
defined as the time from ASCT to death, regardless of the cause. The sta-
tistical analysis was performed for three groups of patients according to
presentation WBC count: WBC<50 K, 50 KWBC<100 K, and
WBC100 K. Cumulative incidence curves were used for RI and NRM in
a competing risks setting, since death and relapse are competing. Probabil-
ities of OS and LFS were calculated using the Kaplan–Meier estimate. Uni-
variate analyses were done using the Gray’s test for cumulative
incidence functions and the log rank test for OS and LFS. Multivariate
analyses were performed by stepwise selection of variables associated
with P< .15 in univariate analysis. All tests were two-sided with the
type I error rate fixed at 0.05. Statistical analyses were performed with
SPSS 19 (SPSS Inc, Chicago, Illinois, USA) and R 2.13.2 (R Development
Core Team, Vienna, Austria) software packages.
3 | RESULTS
3.1 | Patients, disease, and transplant characteristics
We examined data on 1275 patients transplanted between 2005 and
2015 from 98 reporting centers (Supporting Information Appendix).
Table 1 summarizes the baseline demographic and clinical characteris-
tics of the analyzed cohort. Patients with hyperleukocytosis were
younger compared to their nonhyperleukocytosis counterparts, and
were more likely to be FLT3-ITD and NPM1 mutated. Comparing the
three groups of patients according to WBC count (<50 K vs. 50 K-100
K vs. 100 K), the number of cycles to reach first complete remission
(CR1) was similar but HL patients more often received myeloablative
conditioning compared to non-HL patients. Adverse risk cytogenetics
were more common in non-HL patients, whereas patients with
WBC100 K more frequently harbored favorable risk cytogenetics.
3.2 | Overall survival and relapse incidence
The cumulative incidence of relapse at 3 years was 24% (95% CI: 22%
to 27%). LFS and OS at 3 years were 61% (95% CI: 58%-64%) and
66% (95% CI: 63%-69%), respectively. A univariate cox regression
model (Supporting Information Table S1) demonstrated that RI was sig-
nificantly increased in HL patients [29% for WBC 50 K-100 K (95% CI:
22%-37%), and 30% for WBC>100 K (95% CI: 23%-36%) vs. 22% for
non-HL patients (95% CI: 19%-25%); P5 .013]. The three year LFS
rate tended to be lower among patients with hyperleukocytosis but
this did not reach statistical significance [55% (95% CI: 48%-63%) vs.
63% (95% CI: 59%-66%); P5 .066). A similar trend was also noted for
OS (Figure 1). We also note that when we analyzed patients with
hyperleukocytosis (>50K WBC) with regard to their FLT3-ITD/NPM1
mutational status we found that the 52 patients with FLT3-ITD mut/
NPM1wt had a significantly increased risk of RI compared to the other
subgroups (Supporting Information Table S2).
3.3 | NRM and GVHD
Overall, 57 (13%) patients died of nonrelapse etiologies after HSCT.
Leukemia and GHVD constituted the most common causes of patient
death both in non-HL and HL patients (Supporting Information Table
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S3). Overall, grade II-IV acute GVHD was seen in 24% (95% CI: 22% to
27) of the patients analyzed in this cohort, whereas grade III-IV acute
GVHD was experienced by 8% (95% CI: 6%-10%) of patients. The
cumulative incidence of chronic GVHD at 3 years was 42% (95% CI:
39%-45%), and the rate of extensive chronic GVHD was 22% (95% CI:
19%-24%). As shown in Supporting Information Table S1, a univariate
cox regression model indicated that the cumulative incidence of grade
II-IV acute GVHD, chronic GVHD, and extensive chronic GVHD were
comparable in each of the three groups (<50 K vs. 50 K-100 K vs.
100 K). The 3 year incidence of GRFS was significantly increased in
patients with a WBC count<50 K compared to HL patients (45% vs.
39% vs. 36%, respectively; P5 .022).
3.4 | Impact of hyperleukocytosis on outcome
according to donor type
To determine whether donor type, namely matched sibling donors
(MSD) versus matched unrelated donor (MUD), influenced the
TABLE 1 Baseline characteristics of study population
Clinical Parameter WBC<50 (n5 918) 50<WBC<100 (n5 159) WBC>100 (n5198) Pa
Follow up duration in m, median (range) 31.25 (1-121.48 ) 32.77 (2.36-108.36 ) 35.97 (0.69-123.48 )
Age in y, median (range) 52.2(18.1-72.1) 49.1(18.8-70.6) 48.8(18.6-72.1) .016
Gender, n (%)
Male 487 (53.11) 82 (51.57) 95 (47.98) .419
Female 430 (46.89) 77 (48.43) 103 (52.02)
Missing 1 0 0
WBC at diagnosis, median (range) 5.3 (0.2-49.9) 68 (50-99.1) 164.1 (100-780)
Time diagnosis to transplant in days, median (range) 151 (55-393) 140 (67-369) 143 (63-375) .065
ELN cytogenetic risk category, n (%)
Favorable 72 (7.84) 13 (8.18) 28 (14.14) <10-4
Intermediate I 515 (56.1) 108 (67.92) 126 (63.64)
Intermediate II 175 (19.06) 22 (13.84) 25 (12.63)
Adverse 156 (16.99) 16 (10.06) 19 (9.6)
FLT3-ITD status, n (%)
Wild type 647 (70.48) 58 (36.48) 69 (34.85) <10-4
Mutated 271 (29.52) 101 (63.52) 129 (65.15)
NPM1 status, n (%)
Wild type 670 (72.98) 65 (40.88) 78 (39.39) <10-4
Mutated 248 (27.02) 94 (59.12) 120 (60.61)
FLT3-ITD /NPM1 combined status, n (%)
FLT3 wt/NPM1 wt 582 (63.4) 42 (26.42) 49 (24.75) <10-4
FLT3 wt/NPM1 mut 65 (7.08) 16 (10.06) 20 (10.1)
FLT3 mut/NPM1 wt 88 (9.59) 23 (14.47) 29 (14.65)
FLT3 mut/NPM1 mut 183 (19.93) 78 (49.06) 100 (50.51)
Donor type
Matched sibling donor 523 (56.97% ) 109 (55.05% ) 88 (55.35% ) .844
Matched unrelated donor 395 (43.03% ) 89 (44.95% ) 71 (44.65% )
Number of induction cycles to reach CR1, n (%)
1 induction 668 (75.65) 112 (75.17) 151 (79.89) .437
>1 induction 215 (24.35) 37 (24.83) 38 (20.11)
Missing 35 10 9
BM derived graft, n (%) 192 (20.92) 34 (21.38) 56 (28.28) .075
PB graft, n (%) 726 (79.08) 125 (78.62) 142 (71.72)
Conditioning regimen, n (%)
Myeloablative 463 (50.44) 95 (59.75) 116 (58.59) .02
Reduced intensity 455 (49.56) 64 (40.25) 82 (41.41)
aP value of a test of the null hypothesis that all the groups are the same.
Abbreviations: WBC, white blood cells; ELN, European LeukemiaNet; NPM1, nucleophosmin1; FLT3-ITD, FMS-like tyrosine kinase-3 internal tandem
duplication; CR1, first complete.
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outcome of HL patients, a univariate analysis was performed. As shown
in Supporting Information Table S4, in patients receiving grafts from
MSD, grade III-IV acute GVHD was significantly increased in HL
patients compared to non-HL patients (12% vs. 6%) while there was a
trend toward increased RI in HL patients with WBC>100 K which did
not reach statistical significance (33% vs. 24%, P5 .054). In MUD,
chronic GVHD rates were notably lower in HL patients (both >50 K
and >100 K) compared to their non-HL counterparts (38% vs. 30% vs.
48%). RI was statistically marginally inferior in HL patients with
WBC>50 K (25% vs. 20%, P5 .071). Supporting Information Tables
S5 and S6 depict the results of multivariate analyses revealing that in
MSD, HL of over 50 K was significantly associated with an increased
risk of relapse compared to non-HL patients (HR, 1.6; 95% CI, 1.03-
2.49; P5 .035), a finding also observed in MUD (HR, 1.72; 95% CI,
1.005-2.94; P5 .047). GRFS and the incidence of extensive chronic
GVHD was also increased in HL patients with MSD whereas it was not
significantly different among HL patients transplanted from URD.
3.5 | Multivariate analysis of factors impacting on
clinical outcome
To assess the effect of hyperleukocytosis on patient outcome following
transplant, we performed a multivariate analysis using the following
covariates in the regression modeling: WBC at diagnosis, ELN cytoge-
netic risk category, FLT3-ITD status, patient age, donor type, and num-
ber of induction cycles to reach CR1. As illustrated in Table 2 and
Figure 1 the analysis confirmed that increasing WBC count had a sig-
nificant effect on clinical outcome. A WBC count of over 100 K had an
adverse effect on RI (HR, 1.55; 95% CI, 1.14-2.12; P5 .004), LFS (HR,
1.38; 95% CI, 1.07-1.78; P5 .01), and OS (HR, 1.4; 95% CI, 1.07-1.84;
P5 .013). Of note, the effect of hyperleukocytosis on OS was limited
only to HL of over 100 K as a WBC count of 50 K-100 K was not
found to significantly affect OS (HR, 1.25; 95% CI, 0.91-1.7; P5 .15).
GRFS rates were inferior in HL patients both in patients with HL>50K
(HR, 1.3; 95% CI, 1.02-1.65; P5 .03), and those with HL of over 100K
(HR, 1.38; 95% CI, 1.11-1.71; P5 .002).
As summarized in Table 3, grade II-IV acute GVHD, chronic
GVHD, and extensive chronic GVHD rates were not significantly influ-
enced by hyperleukocytosis of any degree. A focused analysis compar-
ing the clinical outcome of patients with hyperleukocytosis of over
TABLE 2 Multivariate analysis of factors impacting on clinical
outcome
Outcome
Hazard ratio
(95% CI) P
Relapse incidence
WBC<50 (reference) 1
WBC 50-100 1.64 (1.17-2.3) .003
WBC 100 1.55 (1.14-2.12) .004
WBC 100 vs. WBC 50-100 0.94 (0.63-1.41) .78
Induction cycles>1 1.46 (1.13-1.89) .003
ELN favorable cytogenetic
risk (reference)
1
Intermediate I 1.75 (1.01-3.04) .044
Intermediate II 2.34 (1.29-4.24) .004
Adverse 3.31 (1.83-5.97) <.001
Unrelated donor vs. matched sibling 0.75 (0.57-0.97) .032
Leukemia-free survival
WBC< 50 (reference) 1
WBC 50-100 1.33 (1- 1.77) .049
WBC 100 1.38 (1.07- 1.78) .013
WBC 100 vs. WBC 50-100 1.03 (0.73-1.46) .83
Induction cycles>1 1.36 (1.1 21.69) .003
ELN favorable cytogenetic
risk (reference)
1
Intermediate I 1.62 (1.06-2.47) .024
Intermediate II 1.89 (1.19-3.01) .006
Adverse 2.59 (1.63-4.11) <.001
Overall survival
WBC< 50 (reference) 1
WBC 50-100 1.25 (0.91-1.7) .15
WBC 100 1.4 (1.07-1.84) .013
WBC 100 vs. WBC 50-100 1.12 (0.77-1.62) .52
ELN favorable cytogenetic
risk (reference)
1
Intermediate I 1.84 (1.14-2.95) .011
Intermediate II 2.13 (1.27-3.56) .003
Adverse 3.06 (1.83-5.12) <.001
FIGURE 1 Relapse incidence and overall survival of transplanted AML patients stratified per initial WBC count
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50 K to patients without hyperleukocytosis confirmed that in HL
patients relapse (HR, 1.59; 95% CI, 1.24-2.05; P5 .0002), LFS (HR,
1.36; 95% CI, 1.1-1.67; P5 .003), and OS (HR, 1.33; 95% CI, 1.07-
1.67; P5 .01) rates were significantly worse compared to non-HL
patients.
4 | DISCUSSION
In this report of a large cohort of transplanted AML patients with
hyperleukocytosis, we show that patients with hyperleukocytosis have
a distinct clinical course resulting in increased RI and inferior leukemia
free survival, GFRS and OS, all of which were prognostically independ-
ent of other standard clinical, cytogenetic, and molecular risk factors
for adverse outcome in AML.
It still remains to be determined whether hyperleukocytotic AML
is a distinct clinical entity, nevertheless our data suggest that patients
presenting with hyperleukocytosis are significantly more likely to har-
bor the double mutation phenotype of FLT3mut/NPM1mut compared to
their non-HL counterparts (50% vs. 19%, P< .001). Notably, HL
patients also had an increased frequency of favorable risk cytogenetics.
While decidedly these observations do not constitute formal proof,
they do hint at the possible unique biology of HL AML. We note that
the data presented is strongly supported by observations made by the
Study Alliance Leukemia study group where HL patients were also
found to be more likely to be FLT3-ITD (45% vs. 16%) and NPM1 (44%
vs. 24%) mutated.18 The Alliance investigators also note that their HL
cohort had fewer patients displaying adverse risk cytogenetics which is
also in line with our data. Previous research from other groups has also
documented an association between hyperleukocytosis and FLT3-
ITD.19,20
Additional salient findings from our study included the following.
First, we establish that HL patients are at a significant risk for increased
leukemia relapse and inferior leukemia free survival, both of which
translated into markedly inferior OS for the group of patients with a
WBC count of over 100 K. Importantly, hyperleukocytosis retained its
prognostic impact following a multivariate analysis accounting for
established adverse risk factors, namely age, cytogenetics, FLT3-ITD,
NPM1, and number of induction cycles to reach CR1, thus confirming
its prognostic significance. In accord with our findings, the Dutch-
Belgian Cooperative Trial Group for Hemato-Oncology and the Swiss
Group for Clinical Cancer Research (HOVON/SAKK) categorize
patients with normal cytogenetics and a WBC>100 K as poor risk
patients21 based on trial results showing inferior OS and disease free
survival for patients with higher WBC counts.22 Interestingly, our data
intersect with the results of two major deep sequencing efforts pub-
lished recently. In the Cancer Genome Project the detrimental effect of
incremental leukocytosis on survival was reaffirmed and was seen to
be in a magnitude roughly proportional to the effect of complex cyto-
genetics.23 Indirect inferences pointing to the prognostic role of WBC
counts may be also made based on the observation that in their analy-
sis, patients with no identified driver mutations had lower WBC counts
than those with identified drivers translating into better clinical out-
comes. In the same vein, data from the Cancer Genome Atlas Research
Network also indicate that a WBC of over 16 000/ul is associated with
inferior survival.24 We note that both studies did not evaluate for
transplant related outcomes.
Our analysis brings about several questions. Should AML patients
presenting with hyperleukocytosis be referred to transplant upfront
(following attainment of first remission) regardless of standard risk fac-
tors such as cytogenetics and molecular markers? Although this ques-
tion cannot be answered conclusively based on data from a
retrospective dataset, nevertheless our findings do suggest that these
patients have an overall high risk clinical course which even transplant
cannot fully overcome, and thus it seems reasonable to assume that
HL patients should be referred to transplant on achievement of remis-
sion. Dovetailing this question it may possible to ask, given the high
rate of relapse following transplant, should patients presenting with
hyperleukocytosis be treated preemptively with either donor lympho-
cyte infusions,25–28 maintenance therapy29–31 or targeted agents32? as
is frequently attempted for patients deemed to be at high risk for
relapse (e.g. complex cytogenetics, positive MRD studies). Lastly, how
does hyperleukocytosis fit into the elaborate molecular based prognos-
tication schemes proposed recently23? Future molecular clinical correl-
ative studies may possibly answer this question.
As with any retrospective analysis we note the inherent limitations
of a multicenter registry and note that additional factors for which we
did not have a fully annotated dataset, such as the initial induction
therapies administered to patients or the minimal residual disease state
at initial remission, may have impacted on long term outcome as well.
TABLE 3 Multivariate analysis of factors impacting transplant
related outcome
Outcome
Hazard ratio
(95% CI) P
Nonrelapse mortality
WBC<50 (reference) 1
WBC 50-100 0.83 (0.47-1.46) .52
WBC100 1.06 (0.67-1.67) .8
WBC100 vs. WBC 50-100 1.27 (0.65-2.48) .47
Age, 10 year increment 1.25 (1.05-1.47) .008
Unrelated donor versus
matched sibling
1.57 (1.09-2.25) .014
Grade II-IV acute GVHD
WBC<50 (reference) 1
WBC 50-100 0.9 (0.62-1.3) .58
WBC100 1.05 (0.76-1.46) .73
WBC100 vs. WBC 50-100 1.17 (0.74-1.83) .48
ELN favorable cytogenetic
risk (reference)
1
Intermediate I 1.8 (1.07-3.03) .025
Intermediate II 1.83 (1.03-3.24) .036
Adverse 1.73 (0.97-3.1) .062
Chronic GVHD
WBC<50 (reference) 1
WBC 50-100 0.9 (0.66-1.22) .52
WBC100 0.83 (0.63-1.1) .19
WBC100 vs. WBC 50-100 0.92 (0.63-1.34) .66
Unrelated donor versus
matched sibling
1.41 (1.14-1.74) .001
Abbreviations: WBC, white blood cells; GVHD, graft versus host disease.
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Simply stated, our analysis shows for the first time that hyperleu-
kocytosis portends an inferior clinical outcome for transplanted AML
patients, independent of cytogenetic and molecular risk factors, and
constitutes a major determinant of long term outcome. We propose
that hyperleukocytosis should be implemented and considered as a
major risk factor for relapse after allogeneic HSCT in patients with
AML.
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